PLRX

Pliant Therapeutics, Inc. (NASDAQ:PLRX) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in South San Francisco, California. The company went public in June 2020 and focuses on discovering, developing, and commercializing novel therapies for the treatment of fibrosis and related diseases. Pliant operates in the highly specialized field of integrin biology, targeting specific cellular receptors that play crucial roles in tissue scarring and fibrotic diseases. The company is currently advancing multiple drug candidates through clinical trials, with its lead program targeting conditions such as idiopathic pulmonary fibrosis and primary sclerosing cholangitis.